C
Cytonus Therapeutics
Cytonus TechnologiesHome - Cytonus Technologies
About Cytonus Therapeutics
Cytonus Therapeutics is a pioneering biotech company focused on revolutionizing cancer therapy and precision medicine through advanced biomolecular delivery solutions. The company operates in the biopharmaceutical market, primarily serving pharmaceutical companies and healthcare providers. Cytonus's core product, the Cargocyte, is a platform technology designed to deliver therapeutic agents directly to targeted tissues, thereby increasing the safety and effectiveness of treatments. The business model revolves around strategic partnerships, licensing, and co-development agreements with leading pharmaceutical companies. These partnerships aim to enhance specific products by leveraging Cytonus's delivery technology, creating significant value for both parties. Revenue is generated through licensing fees, co-development funding, and potential royalties from commercialized products. Cytonus also focuses on attracting and retaining top talent to drive innovation and achieve its mission of improving health outcomes globally.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Diego, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 58.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Oncology, Biotechnology, Spinout, Precision Medicine, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2023 | $12M | $47M | Gemseki Fund · KreaMedica · WSGR Fund · Partners Investment | ↗ |
| EARLY VC✓Equity / VC | Feb 2023 | $0 | — | Nextgen Partners · Proxima Ventures · Partners Investments | ↗ |
Growth signals
Latest recorded traffic for Cytonus Therapeutics is 6.3K monthly website visits, up 2525% over the last three months. Cytonus Therapeutics's team declined 41.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institutes of Health
California Institute for Regenerative Medicine
Series A8 investors entered at this stage
Nextgen Partners
Proxima Ventures- PIPartners Investments
Partners Investment- GFGemseki Fund
KreaMedica- WFWSGR Fund
Creative Ventures
Other known investors2 additional known investors
University of California, San Diego
Endless Frontier Labs
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cytonus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cytonus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.